BMS follows Merck's lead, sues government over drug pricing negotiation
Late-stage pipeline for idiopathic pulmonary fibrosis is small but growing
Eli Lilly's Mounjaro is primed to surpass Novo Nordisk's popular diabetes and obesity duo
More payers could stanch off-label use of Ozempic
*please scroll down for all the latest news*
